RenovoRx Inc (RNXT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.39+0.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNXT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 256.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RNXT — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-07-02
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock (the “Common Stock”) had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Mini…
Why it matters: Updates on this notice will affect how investors feel and stock prices.
Worry ifThey announced plans to fix the delisting notice. They will follow the rules.
Less concerning ifNasdaq may take more steps about delisting or ongoing non-compliance.
Why it matters: Reaching this goal shows good growth and customer use of RenovoCath.
Supportive ifBy December 2026, there will be 36 or more active commercial cancer centers.
Worry ifActive commercial cancer centers stay below 36 by end of 2026.
Why it matters: If cash reserves drop below $9.5 million, it raises concerns about funding operations. This could impact growth plans.
Worry ifCash reserves were over $9.5 million. This shows financial stability.
Less concerning ifCash reserves were below $9.5 million. This signals possible funding issues.
Why it matters: Completing enrollment is key for moving the trial forward and future sales.
Supportive ifEnrollment is complete with 114 patients now in the study.
Worry ifEnrollment completion is delayed beyond mid-2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$256 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $679 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,534 loss on $10,000 · 45.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Fixing the Nasdaq compliance issue is key. It helps keep the company's listing and investor trust.
Worry ifA public announcement was made. It was about meeting Nasdaq listing requirements.
Less concerning ifThere are more notices of non-compliance from Nasdaq.
Why it matters: If the health care sector shows renewed growth, it could benefit RenovoRx. This may improve investor sentiment.
Supportive ifHealth care sector revenue growth re-accelerates back toward its highs.
Worry ifSector growth is slowing down. This means RenovoRx faces ongoing challenges.
Why it matters: High cash burn limits growth potential. Monitoring this helps assess financial health.
Worry ifCash burn reported below $3 million in Q2.
Less concerning ifCash burn reported above $3 million in Q2.
Why it matters: Meeting this target would show strong momentum towards the 2026 revenue goal of $3-4 million.
Supportive ifQ2 revenue reported at or above $1.5 million, indicating strong growth.
Worry ifQ2 revenue falls below $1.5 million, suggesting slower growth than expected.
Why it matters: If Q2 revenue is higher, it shows strong growth and momentum.
Supportive ifQ3 revenue over $909,000 shows ongoing growth in commercial use.
Worry ifQ3 revenue is below $909,000. This shows less commercial activity.
Why it matters: Staying listed is crucial for access to capital and investor confidence. Non-compliance could hurt growth.
Worry ifNasdaq says RenovoRx is back in line with listing rules.
Less concerning ifNasdaq issues a further notice of delisting.
Why it matters: Fixing the compliance issue is important. It helps keep the company's listing and investor trust.
Worry ifThe company said it is following the rules for Nasdaq listings.
Less concerning ifFurther notice of delisting or failure to comply with Nasdaq rules.
Why it matters: What key opinion leaders say can change how investors view and use RenovoCath.
Watch forGood feedback or new partnerships may be shared during the webinar.
Also watch forBad feedback or no new partnerships may be shared during the webinar.
Why it matters: If revenue goes up, it shows the company is still growing.
Supportive ifQ3 revenue is over $909,000. This shows RenovoCath is still growing.
Worry ifQ3 revenue is under $909,000. This means less commercial activity.
Why it matters: Updates on the Nasdaq listing are very important. A delisting could hurt investor confidence.
Worry ifThey announced that they meet Nasdaq listing rules.
Less concerning ifThere were more notices of delisting or not following Nasdaq rules.